Кращі подкасти про Vjhemonc (2025)

V

VJHemOnc Podcast

1
FLT3-ITD+ AML: recent trial updates, novel approaches, and MRD 18:39

22 години тому18:39

18:39

This podcast focuses on FLT3-ITD-positive acute myeloid leukemia (FLT3-ITD+ AML), featuring experts Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Harry Erba, MD, PhD, …

V

VJHemOnc Podcast

1
Extramedullary disease in multiple myeloma: biology, management strategies, & the RedirecTT-1 trial 16:07

8 днів тому16:07

16:07

In this episode of the VJHemOnc Podcast, we dive into one of the more aggressive and challenging manifestations of multiple myeloma, extramedullary disease (EMD). We are joined by experts Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, Saurabh Zanwar, MD, MBBS, M…

V

VJHemOnc Podcast

1
iwMPN 2025 highlights: novel approaches to the upfront management of myelofibrosis, cardiovascular health in MPNs, & more 23:30

15 днів тому23:30

23:30

In this week’s VJHemOnc podcast, we’ll be sharing highlights in myeloproliferative neoplasms (MPNs) from the recent 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025. First, you will hear a roundtable discussion, in which Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center…

V

VJHemOnc Podcast

1
Managing CNS lymphoma: expert insights and updates from ICML 2025 23:09

18 днів тому23:09

23:09

In this episode of the VJHemOnc podcast, we are joined by experts Kathryn Tringale, MD, UC San Diego Health, San Diego, CA, and Nikita Dave, MD, University of Pennsylvania, Philadelphia, PA, who share their perspectives on the management of patients with central nervous system (CNS) lymphoma from the 18th International Conference on Malignant Lymph…

V

VJHemOnc Podcast

1
iwMDS wrap-up: translating research into practice to optimize patient care 23:40

29 днів тому23:40

23:40

VJHemOnc recently attended the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal. This episode features experts Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, Elizabeth Griffiths, MD, Roswell Park Comprehensive Cancer Center, Buffalo,…

V

VJHemOnc Podcast

1
Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification 20:33

рік тому20:33

20:33

Today’s episode of the VJHemOnc podcast focuses on the targeting of mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs) – a trending topic in the field! You will hear leading experts Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris …

V

VJHemOnc Podcast

1
Treating elderly or unfit patients with AML: current approach and future directions 19:53

рік тому19:53

19:53

This episode of the VJHemOnc podcast focuses on the treatment of elderly or unfit patients with acute myeloid leukemia (AML). Featuring experts Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine,…

V

VJHemOnc Podcast

1
Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more! 19:02

рік тому19:02

19:02

VJHemOnc recently attended the 2025 ASCO Annual Meeting in Chicago, IL, where we gained insights into the latest advancements in hematologic oncology. In this episode, leading experts Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Andrew Kuykendall, MD, Moffitt Cancer Cent…

V

VJHemOnc Podcast

1
CHIP & CCUS: advances in understanding and should we treat these precursor conditions? 16:48

рік тому16:48

16:48

In this episode of the VJHemOnc podcast, we explore clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - conditions increasingly recognized as early indicators of myelodysplastic syndromes and acute myeloid leukemia. Joining the discussion are leading experts George Vassiliou, MBBS, PhD, The U…

V

VJHemOnc Podcast

1
Diagnosing amyloidosis: identifying early signs, appropriate diagnostic tests, and challenges that remain 21:27

рік тому21:27

21:27

In this episode of the VJHemOnc podcast, we are joined by Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, a leading expert in the field, to discuss the complexities surrounding the diagnosis of amyloidosis, including both the light chain and ATTR subtypes. The conversation covers early clinical signs that clinicians often overlook, key differenc…

V

VJHemOnc Podcast

1
IPIG 2025 Highlights: challenging situations in PNH, updates from the COMMODORE trials, and more 20:16

рік тому20:16

20:16

VJHemOnc was the official media partner for the recent 2nd International PNH Interest Group (IPIG) Conference held in Paris, France. In today’s podcast episode, you will hear some highlights from the event from leading experts in the field of paroxysmal nocturnal hemoglobinuria (PNH). First, Jens Panse, MD, Aachen University Hospital, Aachen, Germa…

V

VJHemOnc Podcast

1
Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease 11:43

рік тому11:43

11:43

In this episode of the VJHemOnc podcast, join us for an insightful conversation with Dr Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Dr Collins discusses the significant shifts in treatment approaches for patients with advanced-stage classical Hodgkin lymphoma over the past decade. He…

V

VJHemOnc Podcast

1
Gene therapy in sickle cell disease: patient selection, potential complications, & more 21:19

рік тому21:19

21:19

In this episode of the VJHemOnc podcast you will hear from Akshay Sharma, MBBS, MSc, St. Jude Children’s Research Hospital, Memphis, TN, who takes a deep dive into gene therapy for the treatment of sickle cell disease (SCD). Dr Sharma begins by discussing the status of gene therapy in SCD, outlining considerations for clinicians when selecting pati…

V

VJHemOnc Podcast

1
Highlights from iwCAR-T 2025: improving the efficacy and safety of CAR T-cells & access in the community 23:38

рік тому23:38

23:38

Today's VJHemOnc podcast features discussions from the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, which was held recently in Miami, FL. First you will hear from Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, Mohammad Rashidian, PhD, Dana-Farber Cancer Institute, Boston, MA, Michael Jain, MD, PhD, H. Lee Moffitt Cancer …

V

VJHemOnc Podcast

1
Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy 19:49

рік тому19:49

19:49

This episode features leading experts Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, and Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, who provide key insights into the management of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), guided by the latest ESMO clinical practice recommendations.…

V

VJHemOnc Podcast

1
Highlights from iwMyeloma 2025: trial updates and practical considerations 35:15

рік тому35:15

35:15

VJHemOnc was delighted to be media partners for the 18th International Workshop on Multiple Myeloma (iwMyeloma), held in Miami, FL. This podcast episode features highlights from the meeting. First, you will hear from Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL…

V

VJHemOnc Podcast

1
Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment 34:35

рік тому34:35

34:35

In this VJHemOnc podcast, experts Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy, and Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, provide insights into the latest updates to the ESMO clinical practice gui…

V

VJHemOnc Podcast

1
Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more 22:53

рік тому22:53

22:53

In this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus on the prevention and management of graft-versus-host disease (GvHD) and infections associated with stem cell transplantation (SCT). You will also hear about the potential of artificial intelligence (AI) in hematology and transplantat…

V

VJHemOnc Podcast

1
Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more! 46:21

рік тому46:21

46:21

This podcast episode features experts Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who discuss the sequencing of therapies in relapsed/refractory (R/R) non-Hod…

V

VJHemOnc Podcast

1
Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms 18:06

рік тому18:06

18:06

CAR T-cell therapy has revolutionized the lymphoma treatment landscape in recent years. In this episode, we delve into cutting-edge CAR strategies being investigated for lymphoma, including allogeneic products, trispecific CARs, and more. Key highlights include insights into CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T-cel…

V

VJHemOnc Podcast

1
Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more! 23:26

рік тому23:26

23:26

Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring the addition of targeted agents. This podcast focuses on approaches being explored to optimize induction therapy in AML, featuring experts Tapan Kadia, MD, The University of Texas MD Anderson Can…

V

VJHemOnc Podcast

1
Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance 16:52

рік тому16:52

16:52

BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted therapy option for patients. In this podcast, you will hear from Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, Julie Vose, MD, Unive…

V

VJHemOnc Podcast

1
Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more! 27:48

рік тому27:48

27:48

In recognition of Myeloma Awareness Month 2025, this podcast explores key unmet needs and unanswered questions in myeloma research and patient care, offering insights and strategies for healthcare professionals to address them. The discussion centers on four topics: the treatment of smoldering myeloma, managing frail and elderly patients, challenge…

V

VJHemOnc Podcast

1
CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes 18:39

рік тому18:39

18:39

CAR T-cell therapy has become an established treatment for several hematological malignancies, including acute lymphoblastic leukemia (ALL), and has significantly changed the therapeutic landscape for patients. In this podcast episode, renowned experts will share insight into the use of CAR-T in ALL, including updates of pivotal trials, novel appro…

V

VJHemOnc Podcast

1
Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more! 13:15

рік тому13:15

13:15

Today's podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, from the 66th ASH Annual Meeting and Exposition. They share their key highlights in amyloidosis fr…

V

VJHemOnc Podcast

1
Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia 18:27

рік тому18:27

18:27

This episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear the latest updates in sickle cell disease (SCD), thalassemia, and hemophilia from leading experts. First, Sophia Delicou, MD, H…

V

VJHemOnc Podcast

1
Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025 18:29

рік тому18:29

18:29

This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. In this episode, experts Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Cen…

V

VJHemOnc Podcast

1
Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML 28:59

рік тому28:59

28:59

In this podcast, we bring you exclusive updates on acute myeloid leukemia (AML) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear insights into novel approaches to frontline chemotherapy and BCL2 inhibition from experts Ioannis Mantzaris, MD, Montefiore Medical Center/…

V

VJHemOnc Podcast

1
Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more! 22:21

рік тому22:21

22:21

This podcast episode covers key highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. First, you will hear key trial updates in myelofibrosis (MF) from Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, Lucia Masarova, MD, The Univ…

V

VJHemOnc Podcast

1
Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting 31:20

рік тому31:20

31:20

Today's podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. First, you will hear from Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, Catherine Diefenbach, MD, NYU Langone, New York, NY, and Jia …

V

VJHemOnc Podcast

1
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS 19:02

рік тому19:02

19:02

This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. This episode focuses on updates in myelodysplastic syndromes (MDS). You will hear insights into managing anemia in lower-risk MDS (LR-MDS) from Sophie Park,…

V

VJHemOnc Podcast

1
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more! 16:31

рік тому16:31

16:31

VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insights into cutting-edge research in hematological malignancies. This podcast series will cover highlights in a variety of disease areas. Today's episode focuses on chronic lymphocytic leukemia (CLL). You…

V

VJHemOnc Podcast

1
Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents 28:52

рік тому28:52

28:52

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone marrow, and lymph nodes, often associated with a poor prognosis. In this podcast episode, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an in-depth explo…

V

VJHemOnc Podcast

1
Improving care for patients with SCD: pain management, ongoing projects & unmet needs 16:45

рік тому16:45

16:45

This week's podcast focuses on strategies to improve care for patients with sickle cell disease (SCD), featuring expert insights from the 19th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT 2024), which was held in London, UK. You will hear from Natasha Archer, MD, MPH, Harvard Medical School, Boston, MA, Subarna Chakravorty, MB…

V

VJHemOnc Podcast

1
Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care 34:43

рік тому34:43

34:43

In this podcast, experts Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, share insights into the clinical presentation, diagnosis, and treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN…

V

VJHemOnc Podcast

1
Managing complications associated with WM: Bing-Neel syndrome, acquired von Willebrand disease, & more! 21:36

рік тому21:36

21:36

Today's podcast episode focuses on the management of complications associated with Waldenström's macroglobulinemia (WM), featuring expert insights from the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) held in Prague, Czech Republic. You will hear from Shirley D’Sa, MD, FRCP, FRCPath, University College London, London, UK…

V

VJHemOnc Podcast

1
CAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024 24:59

рік тому24:59

24:59

This week's podcast features discussions on the use of immunotherapy in the treatment of high-risk multiple myeloma (HRMM) from the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM), which took place Charleston, SC. You will hear from experts Ajai Chari, MD, University of California San Francisco, San Francisco, CA, and Krina Patel,…

V

VJHemOnc Podcast

1
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS 22:39

рік тому22:39

22:39

This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix, AZ. You will hear from Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, Guillermo Montalban-Bravo, MD, The Universit…

V

VJHemOnc Podcast

1
Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events 9:29

рік тому9:29

9:29

Today's podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will hear from experts Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, Marek Trněný, MD, PhD, Charles University Hospital, Prague, Czech Republic, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, H…

V

VJHemOnc Podcast

1
An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more! 16:34

рік тому16:34

16:34

Menin inhibitors are emerging as a promising therapeutic approach in acute myeloid leukemia (AML), particularly in patients with specific genetic mutations such as KMT2A-rearranged and NPM1-mutated AML. These inhibitors disrupt the leukemogenic signaling pathways that drive leukemia cell proliferation by blocking the actions of menin. They can help…

V

VJHemOnc Podcast

1
CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024 20:30

рік тому20:30

20:30

Today's podcast features discussions from the 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) which took place in Nice, France. You will hear updates on the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL) from experts Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC, Stephen Schuster,…

V

VJHemOnc Podcast

1
Prolonging remission in AML: current approaches & future outlooks 31:27

рік тому31:27

31:27

Today's podcast features a discussion with leading experts Harry Erba, MD, PhD, Duke University, Durham, NC, Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, on strategies to prolong remission in acute myeloid leukemia (AML). They focu…

V

VJHemOnc Podcast

1
A focus on the use of artificial intelligence to personalize blood cancer care 28:55

рік тому28:55

28:55

Welcome to the final episode of VJHemOnc's Blood Cancer Awareness Month special series! This episode focuses on the role of artificial intelligence (AI) in personalizing blood cancer care. Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the value of AI in hematological oncology and how it is currently used i…

V

VJHemOnc Podcast

1
A focus on pediatric leukemias: trials, treatments, & challenges 17:44

рік тому17:44

17:44

Welcome to the third episode of VJHemOnc’s Blood Cancer Awareness Month special series! The focus of this episode is pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). You will hear from Michele Redell, MD, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, who shares insights into the Pediatric Acu…

V

VJHemOnc Podcast

1
A focus on the psychosocial impacts of living with blood cancer 36:22

рік тому36:22

36:22

Welcome to the second episode of VJHemOnc’s Blood Cancer Awareness Month special series! Today's episode focuses on the psychosocial impacts of living with blood cancer. First, you will hear from Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, who shares the work of the Lymphoma Coalition Global Patient Survey. Next, you will hear insights …

V

VJHemOnc Podcast

1
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment 18:54

рік тому18:54

18:54

Welcome to the first episode of VJHemOnc's Blood Cancer Awareness Month special series! This episode focuses on global perspectives of blood cancers and addresses the disparities that exist in awareness, diagnosis, and treatment. First, Lalit Kumar, MD, MBBS, Artemis Hospital, New Delhi, India, discusses challenges that exist in the management of b…

V

VJHemOnc Podcast

1
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more 11:50

рік тому11:50

11:50

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and platelets, respectively, due to mutations in hematopoietic stem cells. In this podcast, experts Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL; Lucia Masarova, MD, The University of Te…

V

VJHemOnc Podcast

1
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges 18:41

рік тому18:41

18:41

This week's VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually. You hear from experts Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, who discusses key hemophilia clinical trials in 2024, Rad…

V

VJHemOnc Podcast

1
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more 17:29

рік тому17:29

17:29

In myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal Transducer and Activator of Transcription (STAT) and Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) are critical mediators in this process, where dysregulated signaling leads to aberrant hematopoiesis and t…

V

VJHemOnc Podcast

1
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs 11:58

рік тому11:58

11:58

Today’s VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, and Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon. They discuss key updates in si…

Подкасти, які варто послухати

Подкасти на тему Vjhemonc

Подкасти, які варто послухати

Короткий довідник